MI-3

Research use only, not for human use.

MI-3 (Menin-MLL Inhibitor) is an effective inhibitor of Menin-MLL interaction (IC50: 648 nM).

MI-3 (Menin-MLL Inhibitor) is an effective inhibitor of Menin-MLL interaction (IC50: 648 nM).

MI-3 (12.5-50 μM; HEK293 cells) treatment effectively inhibits the menin-MLL-AF9 interaction in human cells.MI-3 (0-1.6 μM; 72 hours; KOPN-8 and MV4;11 cells) treatment shows an effective and dose-dependent growth inhibition in KOPN-8, MV4 and ME-1 cells.MI-3 (12.5-50 μM; 48 hours; MV4;11 cells) treatment results in a substantial, and dose-dependent increase in Annexin V and AnnexinV/propidium iodide (PI) cells, demonstrating an increase in the number of cells undergoing apoptosis.MI-3 (6.25-25 μM; 6 days; THP-1 cells) treatment results in substantially reduced expression of HOXA9 and MEIS1. Western Blot Analysis Cell Line:HEK293 cells Concentration:12.5 μM, 25 μM, 50 μM Incubation Time:Result:Very effectively inhibited the menin-MLL-AF9 interaction in human cells.Cell Viability Assay Cell Line:KOPN-8 and MV4;11 cells Concentration:0 μM, 0.4 μM, 0.8 μM, 1.2 μM, 1.6 μM Incubation Time:72 hours Result:Showed an effective and dose-dependent growth inhibition in KOPN-8 and MV4;11 cells.Apoptosis Analysis Cell Line:MV4;11 cells Concentration:12.5 μM, 25 μM, 50 μM Incubation Time:48 hours Result:Resulted in an increase in the number of cells undergoing apoptosis.RT-PCR Cell Line:THP-1 cells Concentration:6.25 μM, 12.5 μM, 25 μM Incubation Time: 6 days Result:Resulted in substantially reduced expression of HOXA9 and MEIS1.

——

MI3 | MI 3 | MI-3

Apoptosis

p53

Menin-MLL

Cancer

——

1271738-59-0

375.55

C18H25N5S2

>98% (HPLC)

DMSO : 8.33 mg/mL. 22.18 mM;

CC(C)c1nc(N2CCN(CC2)C2=NCC(C)(C)S2)c2ccsc2n1

4-[4-(5,5-dimethyl-4H-1,3-thiazol-2-yl)piperazin-1-yl]-6-propan-2-ylthieno[2,3-d]pyrimidine

(-20℃)

With Ice Pack

≥ 2 years